Filtered By: Topstories
News

Sanofi denies negligence in Dengvaxia matter


Pharmaceutical company Sanofi Pasteur on Monday stressed it has not been negligent regarding its anti-dengue vaccine Dengvaxia.

"We have not seen any default or any negligence on the part of the company but of course, we keep monitoring our products. Each time we see an adverse event we communicate," Sanofi Pasteur vice president Thomas Triomphe said in a Senate hearing.

"We'll keep working for any such thing as adverse events," Triomphe added.

"For example, we have processes in place for every single product in every single country where every single case of adverse event is monitored, checked, validated by doctors. There is an official report being produced and then they work with the company to see what's the causality of the adverse event," he said.

Just last month, the company advised against giving Dengvaxia to those who do not have a prior dengue infection.

"In individuals who have not been previously infected by dengue virus, there is an increased risk of hospitalization for dengue and severe dengue, predominantly Grade I or II Dengue Hemorrhagic Fever (DHF)," Sanofi said in a statement.

The Department of Health launched its immunization program against dengue using Dengvaxia in April 2016. According to the department, at least 800,000 public school students in Central Luzon, Calabarzon, Metro Manila, and Cebu have received doses. — Jon Viktor D. Cabuenas/BM, GMA News

LOADING CONTENT